Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

  • A. Tsimberidou (Creator)
  • Jamie V. Shaw (Creator)
  • Dejan Juric (Creator)
  • Claire F. Verschraegen (Creator)
  • Amy M. Weise (Creator)
  • John Sarantopoulos (Creator)
  • Gilberto de Lima Lopes (Creator)
  • John Nemunaitis (Creator)
  • Monica Mita (Creator)
  • Haeseong Park (Creator)
  • Barbara Ellers-Lenz (Creator)
  • Hui Tian (Creator)
  • Wenyuan Xiong (Creator)
  • Remigiusz Kaleta (Creator)
  • Razelle Kurzrock (Creator)

Dataset

Description

Abstract Background The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. Methods M2698 was administered as monotherapy (escalation, 15–380 mg daily; food effect cohort, 240–320 mg daily) and combined with trastuzumab or tamoxifen. Results Overall, 101 patients were treated (M2698, n = 62; M2698/trastuzumab, n = 13; M2698/tamoxifen, n = 26). Patients were predominantly aged
Datos disponibles2021
EditorFigshare

Acceder al conjunto de datos

Citar esto